Sign in
Not yet taking people in United StatesPhase 4

Diet, metformin or GLP-1 drug in subtypes of type 2 diabetes

Compares diet, metformin and GLP-1 drugs in prediabetes or diabetes.

Key facts

Who runs it
Stanford University
Where
Stanford, United StatesSee the site
Trial code
Registry title
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
Status
Not yet recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
Nov 2024
Expected to end
Dec 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Metformin
  • GLP-1A
  • MED
Record updated
12 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with prediabetes or mild type 2 diabetes who are not taking diabetes medicines. They will test three treatments over time.

Age
18 to 75 years
Sex
All sexes can join
Disease stage
Prediabetes or mild type 2 diabetes. HbA1c 5.7-8.0% (39–64 mmol/mol) while not on diabetes medicines. BMI ≥23 (≥22 in Asians) but < 45 kg/m2.
Earlier treatment
Cannot be taking diabetes, diabetes-causing or weight loss medicines now. A washout is allowed if the primary physician approves.
Biomarker or test result
HbA1c 5.7-8.0% (39–64 mmol/mol) while not on antihyperglycemic medications.

Main reasons for not taking part

  • Heart or blood vessel event in the last 6 months
  • Active cancer, kidney or liver disease, pregnancy or breastfeeding
  • History of acute pancreatitis, or medullary thyroid cancer in self or family
  • Heavy alcohol use
  • Cannot come to the Stanford CTRU for testing

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • BMI ≥23 (≥22 in Asians) kg/m2 but < 45 kg/m2
  • HbA1c 5.7-8.0% while not on antihyperglycemic medications

Who cannot take part

  • current use of antihyperglycemic, diabetogenic, or weight loss medications (washout allowed if approved by primary physician)
  • active malignancy, kidney/liver disease pregnancy/lactation, chronic inflammatory disease, eating disorder, bariatric surgery
  • history of acute pancreatitis
  • family or personal history of medullary thyroid cancer
  • hct <30, creatinine > 1.4, ALT> 3x ULN
  • Recent (<6mos) CVD event
  • heavy alcohol use
  • physical activity >2 hours/day
  • inability to come to Stanford CTRU for metabolic testing

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Stanford UniversityStanford, United StatesContact: Alina Choi, BSNot yet recruiting

About the trial

What the trial wants to find out

The study team will invite participants with prediabetes or mild diabetes (HbA1c 5.7-7.0) to join a 5-year research study that will define subphenotypes of type 2 diabetes based on underlying physiology (eg insulin resistance, beta-cell dysfunction, incretin defect, liver insulin resistance) and then test the hypothesis that response to three first-line treatments will vary according to metabolic subphenotype. Variables of interest include glucose, cardiovascular risk markers, and weight. Treatments include Mediterranean diet, metformin, and a GLP-1 agonist. Participants will go through an initial screening, followed by three treatment periods, each lasting 4 months with 3 month washout in-between treatment periods. This study will help us understand how personalized treatments can help control blood glucose, reduce cardiovascular risk, and manage weight. While there may be minor side effects-like slight discomfort from blood tests, gastrointestinal symptoms from some of the medications, and small radiation exposure from DXA body scans-the treatments offered in this study have all been well studied and are known to lower risk for diabetes and cardiovascular disease

The 3 groups in the trial

  • Mediterranean Diet/GLP1a/MetforminTreatment being tested

    1. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat. 2. 3 months washout 3. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols. 4. 3 months washout 5. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.

    Treatment: Metformin, GLP-1A, and MED

  • Metformin/Mediterranean Diet/GLP1aTreatment being tested

    1. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week. 2. 3 months washout 3. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat. 4. 3 months washout 5. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.

    Treatment: Metformin, GLP-1A, and MED

  • GLP1a/Metformin/Mediterranean DietTreatment being tested

    1. 16 weeks using GLP1 agonist: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols. 2. 3 months washout 3. 16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week. 4. 3 months washout 5. 16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.

    Treatment: Metformin, GLP-1A, and MED

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
Plain-language title
Diet, metformin or GLP-1 drug in subtypes of type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06682351, who can take part
Record updated
12 November 2024